Amyotrophic lateral sclerosis (ALS) is increasingly recognized to be a multisystem disorder
which includes both clinical and neuropathological features of a frontotemporal lobar …

The human TAR DNA-binding protein (TDP43) colocalizes with ubiquitinated inclusions in
motor neurons in amyotrophic lateral sclerosis (ALS). TDP43 is both a DNA-binding protein …

Respiratory muscle involvement is a recognised, but often late, complication of amyotrophic
lateral sclerosis (ALS). The clinical features and prognosis of 21 patients with respiratory …

Background Neurofilament light chain (NfL) is a promising blood biomarker in genetic
frontotemporal dementia, with elevated concentrations in symptomatic carriers of mutations in GRN…

Background Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the
pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A …

Objective To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over
12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years …

Importance Behavioral disturbances are core features of frontotemporal dementia (FTD);
however, symptom progression across the course of disease is not well characterized in …

… Christen Shoesmith reports being a site principal investigator for several multicentre
amyotrophic lateral sclerosis (ALS) clinical trials. In the last 36 months, Dr. Shoesmith has …

Objective Although the presymptomatic stages of frontotemporal dementia (FTD) provide a
unique chance to delay or even prevent neurodegeneration by early intervention, they remain …

Objective: To specify the presenting symptoms and clinical course of patients with
frontotemporal dementia (FTD) and chromosome 9 open reading frame 72 (C9ORF72) repeat …